Amgen reported solid financial results with successful launches of Prolia and XGEVA, and strategic acquisitions like BioVex, indicating growth potential. While there are challenges with EPOGEN due to regulatory changes, the overall positive outlook and managementâ€™s proactive strategies suggest a favorable short-term impact on the stock.

[1]